$ 25.87
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment...
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers.
Target Price
The average target price of SMMT is 31 and suggests 22% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
